<span item_type="fundamental" item_id="a37594b7c1f96f7248065b9aba57274c" counter_id="ST/US/CLDWW" env="prod"></span><span item_type="announcement" item_id="547275059770561281" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -1.99.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -5.757 M.</p><p></p><h3>Net Loss</h3><p>The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss of $7.4 million, or $16.75 per share, for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm"></span></p><h3>Research and Development Expenses</h3><p>Research and development expenses were $2.6 million for the three months ended June 30, 2025, compared to $2.2 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm"></span></p><h3>General and Administrative Expenses</h3><p>General and administrative expenses were $3.1 million for the three months ended June 30, 2025, compared to $3.6 million for the comparable period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm"></span></p><h3>Cash and Cash Equivalents</h3><p>The company had approximately $5.3 million in cash and $0.1 million in restricted cash as of June 30, 2025, compared to $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Calidi Biotherapeutics anticipates filing an IND for CLD-401 by the end of 2026 and has received FDA Fast Track Designation for CLD-201, indicating potential advancements in their therapeutic pipeline. The company aims to leverage its RedTail platform to deliver genetic medicines to metastatic sites, which could represent a significant breakthrough in oncolytic viruses and tumor-targeted gene therapies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm"></span></p>

CALIDI BIOTHERAPEUTICS INC C/WTS 14/03/2028 (TO PUR COM) | 8-K: FY2025 Q2 EPS: USD -1.99